NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, April 14, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on April 14th

• Equities are little changed Tuesday morning after the S&P 500 gained 1% yesterday and is clinging to optimism for a longer-term ceasefire in the Middle East.  
• OpenLoop Health CEO Dr. Jon Lensing will join NYSE Live this morning to discuss the company’s expansion into sleep diagnostics in partnership with Happy Sleep.
• Gold medalists Breezy Johnson and Kate Delson will deliver remarks, ring the Opening Bell, and speak to Kristen Scholer after markets open this morning.
• IonQ (NYSE: IONQ) Chairman and CEO Niccolo de Masi will celebrate World Quantum Day at the NYSE and join Taking Stock this afternoon.

Opening Bell
Olympic Gold Medalist Breezy Johnson and Paralympic Gold Medalist Kate Delson ring the Opening Bell

Closing Bell
IonQ (NYSE: IONQ) celebrates World Quantum Day

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Diversified Energy Company CEO Rusty Hutson, Jr. rang the bell.

SYDNEY, April 14, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.

The Agreement relates to Nucleus RadioPharma’s state-of-the-art facility in Rochester, Minnesota, which is capable of manufacturing around 50,000 patient doses per year, and future production in Spring House, Pennsylvania. The Spring House facility is a 47,000 square foot site that is planned to open in 2028, enabling broad coverage across the northeast of the US with up to 600,000 doses of ⁶⁴Cu-SAR-bisPSMA per year. Together, these two facilities in Minnesota and Pennsylvania will provide access to key commercial markets with manufacturing and distribution to all 50 states in the US and select international sites, including Europe.

The Commercial Manufacturing Agreement further builds on Clarity’s existing partnership with Nucleus RadioPharma with a Master Services Agreement and ⁶⁷Cu-SAR-bisPSMA Clinical Supply Agreement in place from November 2024¹, covering the existing site in Rochester with additional facilities in Pennsylvania² and future strategic sites to expand patient access.

This Agreement represents an important step in Clarity’s continued build out of its manufacturing capabilities ahead of ⁶⁴Cu-SAR-bisPSMA’s anticipated commercial launch upon successful completion of Phase III registrational trials with this product, AMPLIFY³ and CLARIFY⁴, and subsequent US Food and Drug Administration (FDA) New Drug Application (NDA) approval.

Geoffrey Johnson, MD, PhD, Chief Scientific Officer of Nucleus RadioPharma, commented, “Nucleus RadioPharma is excited to produce a next-generation diagnostic imaging agent, ⁶⁴Cu-SAR-bisPSMA, that data shows is capable of visualising tiny prostate cancer lesions that the current standard of care prostate specific membrane antigen (PSMA) positron emission tomography (PET) fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes and I firmly believe that seeing is saving. At Nucleus RadioPharma, we are proud to be driving demonstrable advances at the cutting edge of theranostics.”

Stephen Hahn, MD, Chief Executive Officer of Nucleus RadioPharma, commented, “We are pleased to continue growing our partnership with Clarity through this new Commercial Manufacturing Agreement. At Nucleus RadioPharma, we share Clarity’s goal of improving treatment outcomes for patients with cancer and look forward to delivering novel products to people in need of better diagnostic and therapeutic options. ⁶⁴Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics.”

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, “Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of ⁶⁴Cu-SAR-bisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product, given the promising data we have seen in the clinic to date. With large-scale drug product manufacturing, reinforced by large-scale copper-64 production, we will be able to provide ⁶⁴Cu-SAR-bisPSMA on demand through centralised manufacturing and distribution, broadly with sites servicing the entirety of the US and beyond, including sites close to areas of high demand. The half-life of copper-64 gives us the freedom to deliver a number of models in order to meet the future demand for our products.

“Together with Clarity’s existing copper-64 supply agreements with SpectronRx, Nusano and Theragenics, as well as a ⁶⁴Cu-SAR-bisPSMA commercial manufacturing agreement with SpectronRx, the new Agreement with Nucleus RadioPharma further enhances Clarity’s broad network of high-volume production in distinct US geographies, building a tiered approach with regional distribution. The network is designed to support commercial-scale demand with secure, seamless and abundant supply and manufacturing.

“Nucleus RadioPharma is a trusted partner with extensive expertise in radiopharmaceuticals across not only the supply and manufacturing side, but also with a unique insight into the impact that radiopharmaceuticals can have on the healthcare system, treating clinicians and their patients. We look forward to continuing to work with their team as we continue to deliver on our promise of improving treatment outcomes for patients with cancer.”

The Commercial Manufacturing Supply Agreement is effective as of 14 April 2026. Cancellation and extension provisions are aligned with industry standard rates.

Disclaimer

⁶⁴Cu-SAR-bisPSMA and ⁶⁷Cu-SAR-bisPSMA are unregistered products. Their safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Nucleus RadioPharma

Nucleus RadioPharma is an innovative CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, the company provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Nucleus RadioPharma’s technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Recognized for its flexible approach, the company offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle. Backed by Eclipse, Mayo Clinic, AstraZeneca, GE HealthCare, Echo Global, Fox Chase Cancer Center, Granger Management, Mercy Health, and University of Missouri, Nucleus RadioPharma stands well-supported by leading institutions and organizations committed to advancing healthcare through innovative solutions.
Please visit nucleusrad.com and follow on LinkedIn for more information.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.
www.claritypharmaceuticals.com

References

1. Clarity Pharmaceuticals. Clarity and Nucleus RadioPharma sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement. https://www.claritypharmaceuticals.com/news/nucleus/
2. Nucleus RadioPharma Expands Radiopharmaceutical Research, Development and Manufacturing Capacity, Addressing Nationwide Supply Chain Constraints, BusinessWire, 21 October 2024, https://www.businesswire.com/news/home/20241021820034/en/Nucleus-RadioPharma-Expands-Radiopharmaceutical-Research-Development-and-Manufacturing-Capacity-Addressing-Nationwide-Supply-Chain-Constraints
3. ClinicalTrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06970847
4. ClinicalTrials.gov Identifier: NCT06056830. https://clinicaltrials.gov/study/NCT06056830

This announcement has been authorised for release by the Executive Chairperson.

New Powered by Apkudo technology for buff and polish combines advanced plasma treatment and precision automation to accelerate screen restoration at scale for global refurbishment leaders.

BALTIMORE, April 14, 2026 /PRNewswire/ — Apkudo, the Device Passport™ Platform company, today announced that Qates joined the Powered by Apkudo ecosystem, with the launch of the Apkudo Buff-Polish system. This industrial-grade screen restoration solution is designed for high-volume device processors, carriers, and original equipment manufacturers seeking to maximize the resale value of pre-owned assets. By integrating Qates’ specialized hardware with the Apkudo platform, customers unlock a scalable way to turn scratched screens into like-new, revenue-ready devices.

Qates Powered by Apkudo Buff-Polish Product Image

Cosmetic condition, particularly screen quality, is one of the strongest predictors of resale value in the secondary device market, with scratched displays often triggering double-digit price reductions or costly replacements. Traditional refurbishment often requires costly screen replacements or manual polishing processes that are difficult to scale and frequently lead to inconsistent quality and lower margins for high-volume operators. As consumer demand for pristine used devices increases, the industry needs a repeatable, data-driven method to restore screens without compromising device integrity.

The Qates system offers an easy-to-scale, automated solution that restores screens to a high-quality finish while protecting the device’s original display. This efficient process removes scratches more effectively than traditional methods without the mess or complicated setup usually required for restoration. Each system can handle 12 devices per hour, often enabling businesses to more than double their typical output with a small team. Unlike standalone cosmetic restoration tools, every Buff-Polish action is automatically recorded in the Apkudo Device Passport, creating a permanent, auditable record of improvement that travels with the device across owners, channels, and markets.

“As part of the Powered by Apkudo ecosystem, the Qates system connects physical restoration with digital verification, turning cosmetic improvements into durable, market-recognized value,” said Josh Matthews, CEO and Co-Founder of Apkudo. “This is not just about polishing glass; it is about using data and precision to unlock the full financial and circular potential of every asset.”

Strategic Benefits for Asset Owners

• Higher residual value: Eliminate scratches that directly reduce resale prices
• Lower refurbishment cost: Avoid unnecessary screen replacements
• Verified trust: Every improvement recorded in the Device Passport
• Operational scale: High throughput without expanding facility footprint
• Sustainable growth: Extend device lifespan and reduce parts dependency

Learn more about Apkudo’s Device Passport platform and the new Buff-Polish solution by visiting apkudo.com. 

About Apkudo
Apkudo is the Device Passport Platform for the connected device ecosystem. We capture and unify data from every program, transaction, and touchpoint across a device’s lifecycle, creating a single, trusted Device Passport™ for every asset. For companies that manage, sell, or buy devices, this means a verified record they can act on: to restore buyer confidence, maximize value, and reduce risk at every decision point. Our unique advantage is data fidelity and veracity, built on precision-automated robotics that have processed millions of devices, generating objective, machine-verified data that no competitor can match. To learn more, visit apkudo.com.

Media Contact:
Kristen Barry
SVP Marketing and Communications
kristen.barry@apkudo.com

PALO ALTO, Calif., April 14, 2026 /PRNewswire/ — Hesai Technology (NASDAQ: HSAI; HKEX: 2525), a global leader in lidar solutions, attended MODEX 2026 in Atlanta, showcasing its latest 3D lidar solutions for smart logistics applications. At the event, Hesai highlighted its collaboration with Thoro.ai, a Pittsburgh-based, industry-leading robotics company. Hesai will supply its high-performance mini 3D lidar, the JT128, to power Thoro.ai’s perception platform across a wide range of robotic applications, including the industry’s first safety-certified AI autonomy platform for industrial and commercial robots.

Thoro.ai is a software-first robotics company dedicated to enabling OEMs to launch safety-certified autonomous solutions with minimal in-house development. Through CoreFlex — a unified sensor and software suite — OEMs can accelerate time to market, reduce costs, and scale a single autonomy solution across multiple robot types. High-performance sensors like Hesai’s JT128 are critical to making this versatile architecture a reality, providing reliable data that can be used consistently across different machines and applications.

Hesai’s collaboration with Thoro.ai has already begun with significant developments underway. Four new autonomous mobile robots slated for release next year will all be powered by the JT128 lidar. Designed for various workflows across cleaning and material handling, this integration highlights the scalability of CoreFlex and the JT128’s ability to accelerate a wide range of autonomous applications.

With its slim 30 mm window height and a 70% smaller volume compared to similar products, the JT128 can be easily integrated into machines of all sizes, from small cleaning robots to large industrial robots. Its compact form factor helps Thoro.ai streamline hardware integration and simplify development, enabling OEM partners to adopt autonomy faster.

In addition to its compact size, the JT128 features the world’s widest 360° × 187° ultra-hemispherical field of view, delivering all-around perception coverage with no blind spots. In warehouse environments, some of Thoro.ai’s robots require vertical awareness to detect objects beneath forks and align with rack beams above. The vertical field of view of the JT128 enables true autonomous pallet handling while meeting strict safety standards.

Because lidar actively emits laser light, it is not affected by ambient lighting conditions. This makes the JT128 highly reliable across all of Thoro.ai’s robotic applications, including challenging environments with reflective surfaces and glass.

“At Thoro.ai, we think about each of these OEM partnerships not just as standalone projects, but as part of our CoreFlex autonomy architecture: a modular, safety-certified platform designed to scale across many machine types,” says Patrick Mondi, CEO of Thoro.ai. “The JT series plays a key role in making that possible by giving us reliable, high-fidelity perception that works consistently across very different form factors. This simplifies the integration process for our partners, lowers their development costs, and gets their autonomous solutions to market faster. Hesai’s responsiveness, bug testing, and rapid iteration cycles also align directly with our mission to deliver safe, reliable autonomy at scale.”

The collaboration between Hesai and Thoro.ai marks a significant step forward in the robotics industry. By integrating Thoro.ai’s advanced AI-driven autonomy software with Hesai’s high-performance JT128 lidar, the two companies are enabling OEMs to launch autonomous mobile robots that are safer, more intelligent, and faster to deploy. Visitors are invited to stop by Hesai’s booth (Hall A #5306) at MODEX 2026 to see firsthand how the company’s latest innovations are shaping the future of smart logistics.

DHAHRAN, Saudi Arabia, April 14, 2026 /PRNewswire/ — Aramco Stadium Company, a subsidiary of Aramco, today announced its official launch and the appointment of its inaugural Board of Directors and Chief Executive Officer. The appointments mark a key milestone in activating the company and delivering one of the Kingdom’s most important sports and entertainment development projects, aligning with Saudi Arabia’s Vision 2030 and contributing to its hosting of the 2034 FIFA World Cup.

Aramco Stadium

Fahad Al Dhubaib has been appointed Chairman of the Board of Directors of Aramco Stadium Company, and Mohammed Al Thomairi has been appointed Vice Chairman of the Board. Abdulrahman Alqudaib, Bader Alreziza, Nader Ashoor, Jefferson Slack, and James Bisgrove have also been appointed as Board members. In addition, Matthew Kittle has been named CEO. The board members and executive leadership possess extensive experience and skills in global sports and entertainment development, the management of major facilities and events, and commercial development and financial sustainability.

Located in Al-Khobar, Aramco Stadium is set to open this year with a capacity of 47,000 seats, and it will serve as the home ground for Al-Qadsiah Football Club. The stadium is part of an integrated complex spanning 800,000 square meters designed to welcome local residents and visitors from around the world throughout the year. The stadium is also intended to host international competitions, including the AFC Asian Cup 2027 and the FIFA World Cup 2034, as well as other entertainment events, further strengthening its role in the evolving sports and entertainment landscape of the Kingdom.

Aramco Stadium Company Contact Information

https://www.aramcostadium.com/en

Media Contacts:

Aramco Stadium Public Relations Team
pr@aramcostadium.com

About Aramco Stadium

Aramco Stadium is a state-of-the-art, multi-purpose sports and entertainment venue in Saudi Arabia’s Eastern Province, set within an 800,000+ square meter campus designed as a year-round destination. Built to international tournament standards, the fully air-conditioned stadium is intended to host matches during the 2027 AFC Asian Cup and the 2034 FIFA World Cup, underscoring its leadership within the Kingdom’s expanding global sports portfolio and its alignment with Saudi Vision 2030. Home to Al-Qadsiah FC, Aramco Stadium integrates advanced venue technology and premium hospitality to deliver world-class experiences while anchoring a fence-free campus featuring restaurants, nearly 130,000 square meters of public park space, sports courts, playgrounds, and community programming, establishing a vibrant 365-day destination for residents and international visitors alike.

MILAN, April 14, 2026 /PRNewswire/ — GAC today launches its second model in the fully electric AION product line in Europe’s capital of design Milan: the electric hatchback AION UT. The model was developed by GAC and co-designed by the GAC’s Advanced Design Centre in Milan. AION UT will first go on sale in Finland, Greece, Poland and Portugal this quarter. Other European markets will follow in Q3.

AION UT combines a contemporary design with a spacious interior and advanced intelligence and safety technology. It has a wheelbase of 2,750 mm and an interior space comparable to that of a mid-size sedan. The infotainment system features dual screens: a 14.6-inch touchscreen and an 8.88-inch digital instrument cluster. AION UT meets the highest safety standards, equipped with a double door ring, V-shaped side curtain airbags, and Level 2 ADAS technology.

The range is up to 430 km (WLTP). Charging from 30 to 80% via DC takes 24 minutes. The 0–100 km/h sprint is completed in 7.3 seconds. AION UT is available in two trim levels: Premium and Luxury.

Built in Austria

Like the SUV AION V, introduced in Europe last year, AION UT is assembled at Magna’s facility in Graz. Localization improves supply efficiency and market responsiveness, and marks a strategic shift for GAC: from vehicle exports to deeper, localised roots in Europe. Guided by its “In Europe, for Europe” commitment, GAC aims to actively contribute to the European electric mobility ecosystem, through local manufacturing, regional partnerships, and investment in sustainable mobility.

Designed in Milan

GAC’s European Advanced Design Centre bridges Eastern automotive expertise with European design sensibility, developing vehicles tailored to the European market. Located in Milan’s Via Tortona design district, the Centre brings together an international team of designers working on future mobility concepts, including next-generation electrification technologies. Models such as AION UT illustrate the Centre’s approach: combining GAC’s global technology with the refined aesthetics and craftsmanship that European customers expect.

GAC is working to expand further across Europe through new partnerships and the development of sales and service networks.

Pricing

Depending on the different market conditions, European pricing starts at 27,990 Euros.

About GAC

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

– Real Jongga Kimchi differentiation drives strong Gen Z response at Costco and Loblaws 
– FreshCo expansion to reach 150 stores nationwide in Canada in the second half of the year

SEOUL, South Korea, April 14, 2026 /PRNewswire/ — Kimchi Ramyun, launched by Daesang’s leading Korean food brand Ofood, has surpassed 1 million units in cumulative sales in Canada, carving out a niche market by leveraging Korea’s heritage as the origin of Kimchi.

Since its launch in the Canadian market in October last year, ‘Real Kimchi Ramyun Noodle Soup’ has quickly gained traction, receiving strong positive responses from local consumers. Unlike conventional ramyun products that rely on dried flakes, Ofood Kimchi Ramyun uses real Kimchi from Korea’s No.1* Kimchi brand Jongga, delivering the authentic taste of traditional Korean Kimchi stew. This differentiated approach has contributed to its rapid market growth.

Ofood Kimchi Ramyun is available in two varieties: ‘Real Kimchi Ramyun Noodle Soup’, featuring a spicy soup base, and ‘Real Fiery Kimchi Stir-fried Ramyun’, made with gochujang. Both products use fresh Kimchi instead of dried flakes, offering a crisp texture and deep fermented flavor. While balancing sourness and aroma, the products retain the signature spiciness of Korean ramyun, making them appealing to a wide range of consumers.

Active marketing efforts targeting local Gen Z consumers also contributed to the strong performance. Ofood enhanced brand awareness through outdoor advertising in major Canadian cities and digital campaigns on social media platforms such as Instagram and TikTok. In addition, large-scale sampling events held around major universities, including the University of Toronto, helped expand engagement with younger consumers familiar with Korean culture and bold flavors, leading to actual purchases.

Following strong sales performance, distribution expansion is also accelerating. In addition to existing retail channels such as Costco and Loblaws, Ofood Kimchi Ramyun is now available at FreshCo, where it is currently sold in approximately 70 stores across Canada, with plans to expand distribution to more than 150 locations nationwide in the second half of the year.

Seungin Jung, Head of Global Discovery BO at Daesang, said, “Ofood Kimchi Ramyun is rapidly gaining traction in the Canadian market as a product that allows consumers to enjoy the authentic taste of Korean Kimchi. We will continue to strengthen the presence of K-food in North America through marketing tailored to local consumer lifestyles and expanded distribution channels.”

Meanwhile, Ofood Kimchi Ramyun is also available through major online and offline channels in the United States, including Costco, Kroger, and Amazon, as Daesang continues to expand its global brand activities across the North American market.

About Daesang Corporation 

Founded in 1956, Daesang Corporation is one of the world’s largest producers of fermented food products, with decades of expertise in food manufacturing. The company has grown into a leading global Korean food company through internationally recognized brands such as Jongga and Ofood, offering a broad product portfolio that includes Kimchi, sauces, ready-to-eat meals, and more. Headquartered in South Korea, Daesang operates manufacturing subsidiaries in the United States, Poland, China, Indonesia, and Vietnam. For more information, visit www.daesang.com/en.

About Ofood

Ofood is a global Korean food brand serving up creative experiences and fresh inspiration, making Korean cuisine easy to enjoy anytime, anywhere. With its Korean Twist, Ofood is winning hearts and taste buds all around the world while reimagining Korean food for today’s consumers. With a diverse portfolio spanning sauces, seaweed, and ready-to-eat meals, Ofood exports its products to more than 80 countries, expanding everyday access to K-food for consumers worldwide. For more information, visit www.ofoodglobal.com/